Table 1.
Baseline characteristics of the entire cohort (N = 35)
| Characteristic | Value |
|---|---|
| Age, median (range), y | 67 (38-78) |
| Male | 24 (69%) |
| Race, white | 35 (100%) |
| ECOG performance status score | |
| 0 | 16 (46%) |
| 1 | 17 (49%) |
| 2 | 2 (6%) |
| Eligible for autologous stem cell transplant | 29 (85%) |
| Involved organs | |
| Cardiac | 23 (66%) |
| Renal | 19 (54%) |
| Nerve | 6 (17%) |
| Hepatic | 4 (11%) |
| >1 organ | 15 (43%) |
| Lambda restricted | 26 (74%) |
| BMPCs, median (range), % | 9 (<5%-30%) |
| dFLC, median (range), mg/dL | 29.0 (5.0-109) |
| Serum creatinine, median (range), mg/dL | 1.1 (0.6-1.9) |
| 2012 Mayo AL amyloidosis stage, I/II/III/IV, % | 20/31.4/22.9/25.7 |
| FISH abnormalities (n = 28)* | |
| t(11;14) | 50% |
| del(13q)/monosomy 13 | 43% |
| Trisomies | 32% |
| gain(1q) | 14% |
| del(17p)/monosomy 17 | 11% |
| t(4;14) | 4% |
| t(14;20) | 4% |
| >1 abnormality | 61% |
BMPC, bone marrow plasma cells; dFLC, difference between involved to uninvolved light chains; ECOG, Eastern Cooperative Oncology Group.
*
Four patients had insufficient clonal plasma cells for testing; 3 patients did not have fluorescence in situ hybridization (FISH) testing performed.